# OnCo record paper-nadofaragene-firadenovec-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nadofaragene-firadenovec-lancet-oncol-2021" ;
  schema:name "Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer"@en ;
  schema:description "A single instillation of a virus carrying the interferon gene into the bladder every three months cleared carcinoma in situ in about half of patients who had failed BCG, and became the first gene therapy approved for bladder cancer."@en ;
  schema:url <https://onco.cc/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30540-4>, <https://pubmed.ncbi.nlm.nih.gov/33253641/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(20)30540-4> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Boorjian SA, Alemozaffar M, Konety BR, et al." ;
  onco:cancers <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:drugs <https://onco.cc/drugs/nadofaragene-firadenovec/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .